Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Glaspy

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Oncology (Williston Park, N.Y.)|October 17, 2002
The potential for anemia treatment to improve survival in cancer patientsJohn A Glaspy
The Journal of Supportive Oncology|February 24, 2005
Entering a new era in the management of tumor-associated involutionJohn A Glaspy
Oncology (Williston Park, N.Y.)|December 20, 2003
Hematopoietic management in oncology practice. Part 1. Myeloid growth factorsJohn A Glaspy
Expert Opinion on Emerging Drugs|August 9, 2005
The development of erythropoietic agents in oncologyJohn A Glaspy
Cancer Treatment and Research|November 6, 2010
Randomized controlled trials of the erythroid-stimulating agents in cancer patientsJohn A Glaspy
Annual Review of Medicine|November 5, 2008
Erythropoietin in cancer patientsJohn A Glaspy
Oncology (Williston Park, N.Y.)|October 17, 2002
Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiencyJohn A Glaspy
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Cancer patient survival and erythropoietinJohn A Glaspy
Seminars in Oncology|June 18, 2002
Therapeutic options in the management of renal cell carcinomaJohn A Glaspy
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2008
Erythropoiesis-stimulating agents in oncologyJohn A Glaspy
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Oncology (Williston Park, N.Y.)|October 17, 2002
The potential for anemia treatment to improve survival in cancer patientsJohn A Glaspy
The Journal of Supportive Oncology|February 24, 2005
Entering a new era in the management of tumor-associated involutionJohn A Glaspy
Oncology (Williston Park, N.Y.)|December 20, 2003
Hematopoietic management in oncology practice. Part 1. Myeloid growth factorsJohn A Glaspy
Expert Opinion on Emerging Drugs|August 9, 2005
The development of erythropoietic agents in oncologyJohn A Glaspy
Cancer Treatment and Research|November 6, 2010
Randomized controlled trials of the erythroid-stimulating agents in cancer patientsJohn A Glaspy
Annual Review of Medicine|November 5, 2008
Erythropoietin in cancer patientsJohn A Glaspy
Oncology (Williston Park, N.Y.)|October 17, 2002
Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiencyJohn A Glaspy
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Cancer patient survival and erythropoietinJohn A Glaspy
Seminars in Oncology|June 18, 2002
Therapeutic options in the management of renal cell carcinomaJohn A Glaspy
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2008
Erythropoiesis-stimulating agents in oncologyJohn A Glaspy
Pageof 9